Torrent Pharma announces Q3 FY26 results: net profit growth of 26%
Ahmedabad, 14th February 2026: Torrent Pharmaceuticals Limited (‘’Company”) today announced its financial results for the third quarter of FY 26.
India revenues at Rs 1,798 crores were up 14%. As per AIOCD PharmaTrac secondary market data, IPM growth for the quarter was 10%. Continued volume outperformance over IPM in chronic and sub-chronic therapies led by Cardiac, Gastro, and Diabetes (OAD) segments. For 9M FY26, revenues were Rs 5,430 crores, up by 12%.
Brazil: Brazil revenues at Rs 371 crores, were up by 27%. Constant currency revenues, at R$ 224 million, were up by 10%. As per IQVIA, Torrent grew at 13% vs market growth of 7%; growth was aided by the performance of top brands & recent launches. Torrent has 60 products under ANVISA review. For 9M FY26, revenues were Rs 907 crores, up by 21% (Constant currency revenue: R$ 564 million, up by 13%).
United States: US business revenues at Rs 321 crores, were up by 19%. Constant currency revenues at $36 million, were up by 12% compared to the same period in the previous year. Recent launches have achieved target market shares. For 9M FY26, revenues were Rs 967 crores, up by 21% (Constant currency revenue: $111 million up by 16%).
Germany: Germany revenues at Rs 304 crores, were up by 8%. Constant currency revenues at EUR 29 million, were down by 6%. Growth continued to be impacted due to supply disruption at a third party supplier. For 9M FY26, revenues were Rs 916 crores, up by 7% (Constant currency revenue: EUR 91 million, down by 3%).
Key Highlights for Q3 FY26:
| Revenue at Rs. 3,303 crores, up by 18% YoY | Op. EBITDA* at Rs.1,088 crores, up by 19% YoY |
| Op. EBITDA margin* at 33%; Gross Margin: 76% | Net Profit after tax at Rs. 635 crores, up by 26% YoY |
Performance summary:
| Results | Q3 FY26 | Q3 FY25 | YoY % | 9M FY26 | 9M FY25 | YoY % | ||||
| Rs cr | % | Rs cr | % | Rs cr | % | Rs cr | % | |||
| Revenues | 3,303 | 2,809 | 18% | 9,783 | 8,557 | 14% | ||||
| Gross profit | 2,504 | 76% | 2,136 | 76% | 17% | 7,410 | 76% | 6,512 | 76% | 14% |
| Op EBITDA* | 1,088 | 33% | 914 | 33% | 19% | 3,203 | 33% | 2,757 | 32% | 16% |
| Exceptional item** | (10) | 0% | – | – | – | (23) | 0% | – | – | – |
| PAT | 635 | 19% | 503 | 18% | 26% | 1,774 | 18% | 1,413 | 17% | 26% |
| R&D spend | 154 | 5% | 151 | 5% | 2% | 468 | 5% | 431 | 5% | 9% |
** Exceptional item comprises regulatory & statutory filing fees and other related costs associated with acquisition of J.B. Chemicals & Pharmaceuticals Ltd.
Torrent Pharma, with annual revenues of more than Rs 11,500 crores, is the flagship Company of the Torrent Group, with group revenues of ~Rs 45,000 crores. Post JB Pharma acquisition it is ranked 5th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS), Pain Management and Cosmo-Dermatology.
It is a specialty-focused company with ~76% of its revenues in India from chronic & sub-chronic therapies. It has presence in 50+ countries and is ranked No. 1 amongst the Indian pharma Companies in Brazil and Germany. Torrent has 8 manufacturing facilities, of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing approximately 750+ scientists.
(Disclaimer: The information provided here is investment advice only. Investing in the markets is subject to risks and please consult your advisor before investing.)
(સ્પષ્ટતા: અત્રેથી આપવામાં આવતી તમામ પ્રકારની માહિતી કોઇપણ પ્રકારે રોકાણ/ ટ્રેડીંગ માટેની સલાહ નથી. બજારોમાં રોકાણ જોખમોને આધીન છે અને રોકાણ કરતા પહેલા કૃપા કરીને તમારા સલાહકારની સલાહ લો.)
